Fitero, A.; Negruț, N.; Cseppento, D.C.N.; Tit, D.M.; Negru, P.A.; Bustea, C.; Radu, A.F.; Bungau, S.G. Divergences in Antiviral Therapy for Diabetic Patients with COVID-19. Pharmacophore 2024, 15, 79–89, doi:10.51847/perpvy0am7.
Fitero, A.; Negruț, N.; Cseppento, D.C.N.; Tit, D.M.; Negru, P.A.; Bustea, C.; Radu, A.F.; Bungau, S.G. Divergences in Antiviral Therapy for Diabetic Patients with COVID-19. Pharmacophore 2024, 15, 79–89, doi:10.51847/perpvy0am7.
Fitero, A.; Negruț, N.; Cseppento, D.C.N.; Tit, D.M.; Negru, P.A.; Bustea, C.; Radu, A.F.; Bungau, S.G. Divergences in Antiviral Therapy for Diabetic Patients with COVID-19. Pharmacophore 2024, 15, 79–89, doi:10.51847/perpvy0am7.
Fitero, A.; Negruț, N.; Cseppento, D.C.N.; Tit, D.M.; Negru, P.A.; Bustea, C.; Radu, A.F.; Bungau, S.G. Divergences in Antiviral Therapy for Diabetic Patients with COVID-19. Pharmacophore 2024, 15, 79–89, doi:10.51847/perpvy0am7.
Abstract
Abstract: Background: Patients with diabetes are particularly susceptible to COVID-19 infection, which can result in severe respiratory illness. Methods: This study conducted a comparative as-sessment of the impact of antiviral therapy using molnupiravir and favipiravir in COVID-19 pa-tients with underlying diabetes. A cohort of one hundred individuals infected with SARS-CoV-2, diagnosed with diabetes, and consecutively admitted, was included in the present study. These patients were treated with antivirals according to local guidelines: Group F (51 cases) was treated with favipiravir – 10 days and Group M (49 cases) was treated with molnupiravir – 5 days. Re-sults: In Group F, the average hospitalization was higher than in Group M (11.29±2.27 vs. 7.14±3.16, p
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.